TABLE 2.
Echocardiographic measurements in calcineurin-transgenic mice crossed into the NFATc3-null background at 10 weeks of agea
| Parameter | Mean ± SEM in:
|
|||
|---|---|---|---|---|
| NFATc3+/+ mice (n = 5) | NFATc3−/− mice (n = 9) | CnTG NFATc3+/+ mice (n = 10) | CnTG NFATc3−/− mice (n = 7) | |
| Septum (mm) | 0.68 ± 0.05 | 0.66 ± 0.04 | 0.79 ± 0.04∗ | 0.68 ± 0.04∗∗ |
| LV free wall (mm) | 0.59 ± 0.05 | 0.62 ± 0.04 | 0.71 ± 0.04∗ | 0.56 ± 0.05∗∗ |
| LVEDD (mm) | 3.68 ± 0.12 | 3.42 ± 0.12 | 4.41 ± 0.24∗ | 3.83 ± 0.28∗∗ |
| LVESD (mm) | 2.34 ± 0.14 | 2.13 ± 0.12 | 3.30 ± 0.17∗ | 2.95 ± 0.20∗∗ |
| FS (%) | 36.5 ± 2.6 | 37.6 ± 2.5 | 24.7 ± 2.2∗ | 22.5 ± 2.5∗ |
a
NFATc3 wild-type mice and NFATc3-null mice were compared at baseline or when crossed into the calcineurin-transgenic background by echocardiography. Each mouse was measured three times (5 to 10 mice in each group). LV, left ventricle measured in diastole; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension. Fractional shortening (FS) was calculated as (LVEDD − LVESD)/LVEDD × 100. ∗, P < 0.05 versus NFATc3+/+ mice; ∗∗, P < 0.05 versus CnTG NFATc3+/+ mice. n = number of mice.